Cardiac allograft vasculopathy by intravascular ultrasound in hearttransplantpatients. Substudy fromthe everolimus versus mycophenolate mofetil randomized, multicenter trial

JACC: Heart Failure

Volumn 1, Issue 5, 2013, Pages 389-399

  Kobashigawa, Jon A ^a   Pauly, Daniel F ^b   Starling, Randall C ^c   Eisen, Howard ^d   Ross, Heather ^e   Wang, Shoei Shen ^f   Cantin, Bernard ^g   Hill, James A ^b   Lopez, Patricia ^h   Dong, Gaohong ^h   Nicholls, Stephen J ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e Toronto Hospital   (Canada)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g LAVAL UNIVERSITY   (Canada)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cardiac allograft vasculopathy; Everolimus; Heart transplant; Intravascular ultrasound

Indexed keywords

CHOLESTEROL; CYCLOSPORIN; EVEROLIMUS; GANCICLOVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPERIMMUNE GLOBULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRIACYLGLYCEROL; VALACICLOVIR; VALGANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADULT; AGE; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE COURSE; DONOR AGE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; INCIDENCE; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MAXIMAL INTIMAL THICKNESS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX; THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

CORONARY ARTERY DISEASE; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84885172390     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.07.002     Document Type: Article

References (35)

1. Schmauss D., Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008, 117:2131-2141.
2. Grattan M.T., Moreno-Cabral C.E., Starnes V.A., Oyer P.E., Stinson E.B., Shumway N.E. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261:3561-3566.
3. Kirklin J.K.Y.J., McGiffin D.C., Benza R.L., Tallaj J. Cardiac allograft vasculopathy (chronic rejection). Heart Transplantation 2002, 615-665. Churchill Livingstone, New York, NY. Kirklin JK YJ, D.C. McGiddin (Eds.).
4. Costanzo-Nordin M.R. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. JHeart Lung Transplant 1992, 11:S90-103.
5. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. JHeart Lung Transplant 1998, 17:744-753.
6. Viklicky O., Zou H., Muller V., Lacha J., Szabo A., Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000, 69:497-502.
7. Schuurman H.J., Schuler W., Ringers J., Jonker M. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 1998, 30:2198-2199.
8. Schuurman H.J., Ringers J., Schuler W., Slingerland W., Jonker M. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000, 69:737-742.
9. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties invitro and invivo. Transplantation 1997, 64:36-42.
10. Schuurman H.J., Cottens S., Fuchs S., et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997, 64:32-35.
11. Schuurman H.J., Pally C., Weckbecker G., Schuler W., Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999, 31:1024-1025.
12. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. NEngl J Med 2003, 349:847-858.
13. Kobashigawa J., Miller L., Renlund D., et al. Arandomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998, 66:507-515.
14. Eisen H.J., Kobashigawa J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. JHeart Lung Transplant 2005, 24:517-525.
15. Kobashigawa J.A., Tobis J.M., Mentzer R.M., et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 2006, 6:993-997.
16. Tuzcu E.M., Kapadia S.R., Sachar R., et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. JAm Coll Cardiol 2005, 45:1538-1542.
17. Kobashigawa J.A., Tobis J.M., Starling R.C., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. JAm Coll Cardiol 2005, 45:1532-1537.
18. Eisen H.J., Kobashigawa J., Starling R.C., et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013, 13:1203-1216.
19. Billingham M.E., Cary N.R., Hammond M.E., et al. Aworking formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. JHeart Transplant 1990, 9:587-593.
20. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. JHeart Lung Transplant 2005, 24:1710-1720.
21. Nishimura T., Faul J.L., Berry G.J., Veve I., Pearl R.G., Kao P.N. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001, 163:498-502.
22. Cole O.J., Shehata M., Rigg K.M. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998, 30:2200-2203.
23. Poon M., Marx S.O., Gallo R., Badimon J.J., Taubman M.B., Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. JClin Invest 1996, 98:2277-2283.
24. Marx S.O., Jayaraman T., Go L.O., Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995, 76:412-417.
25. Rzucidlo E.M., Martin K.A., Powell R.J. Regulation of vascular smooth muscle cell differentiation. JVasc Surg 2007, 45:A25-A32.
26. Barilli A., Visigalli R., Sala R., et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res 2008, 78:563-571.
27. Azzola A., Havryk A., Chhajed P., et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004, 77:275-280.
28. Winters G.L., Kendall T.J., Radio S.J., et al. Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. JHeart Transplant 1990, 9:364-371.
29. Eich D., Thompson J.A., Ko D.J., et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. JHeart Lung Transplant 1991, 10:45-49.
30. Escobar A., Ventura H.O., Stapleton D.D., et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1994, 74:1042-1046.
31. Schaffer S.A., Ross H.J. Everolimus: efficacy and safety in cardiac transplantation. Expert Opin Drug Saf 2010, 9:843-854.
32. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. NEngl J Med 1995, 333:621-627.
33. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997, 96:1398-1402.
34. Avery R.K. Viral triggers of cardiac-allograft dysfunction. NEngl J Med 2001, 344:1545-1547.
35. Eisen H., Yang X. The impact of proliferation signal inhibitors on the healthcare burden of major adverse cardiac events following heart transplantation. Transplantation 2006, 82:S13-S18.